Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 15
- 13F valueReported value at the end of Q2 2026
- $6.16M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DWTX, Q2 2026
No superinvestor reported holding DWTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Dogwood Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 22, 2023 (view filing) | Aug 21 | 1 day | Pridgen WilliamDirector | PPurchase | +15.3K | $1.30 | +$19.9K | +41.8%52.0K after | |
| Aug 18, 2023 (view filing) | Aug 17 | 1 day | Duncan Gregory ScottCHIEF EXECUTIVE OFFICER | PPurchase | +25.0K | $1.25 | +$31.3K | +77.0%57.5K after | |
| Dec 12, 2022 (view filing)1:39 PM ET | Dec 8 | 4 days | Whitley Richard JamesDirector | SSale | −1.80K | $0.2591 | −$466.38 | −72.0%700 after | |
| May 24, 2022 (view filing) | May 23 | 1 day | Walsh AngelaSVP OF FINANCE | PPurchase | +2.00K | $4.58 | +$9.16K | +200.0%3.00K after | |
| May 24, 2022 (view filing) | May 23 | 1 day | Duncan Gregory ScottCHIEF EXECUTIVE OFFICER | PPurchase | +7.50K | $4.52 | +$33.9K | +30.0%32.5K after | |
| May 19, 2022 (view filing) | May 18 | 1 day | Whitley Richard JamesDirector | PPurchase | +500 | $4.53 | +$2.27K | +25.0%2.50K after | |
| May 19, 2022 (view filing) | May 18 | 1 day | Pridgen WilliamDirector | PPurchase | +241 | $4.50 | +$1.08K | +0.7%36.7K after | |
| May 18, 2022 (view filing) | May 17 | 1 day | Pridgen WilliamDirector | PPurchase | +13.4K | $4.38 | +$58.9K | +58.4%36.5K after | |
| Mar 30, 2022 (view filing) | Mar 29 | 1 day | Pridgen WilliamDirector | PPurchase | +600 | $4.94 | +$2.96K | +2.7%23.0K after | |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Pridgen WilliamDirector | PPurchase | +2.20K | $5.46 | +$12.0K | +10.9%22.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Dogwood Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,132,486 | $5.04M | 0.14% | −147,514−4.5% | Reduced |
| Millennium Management LLC | 341,814 | $550.3K | 0.00% | +341,814 | New |
| Vanguard Capital Management LLC | 132,154 | $212.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 88,298 | $142.2K | 0.00% | +8,864+11.2% | Added |
| Vanguard Fiduciary Trust Co | 62,736 | $101.0K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 28,546 | $46.0K | 0.00% | +28,516+95,053.3% | Added |
| Northern Trust Corp | 23,779 | $38.3K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 11,742 | $18.9K | 0.00% | +11,742 | New |
| Tower Research Capital LLC (TRC) | 3,093 | $4.98K | 0.00% | −4,974−61.7% | Reduced |
| Morgan Stanley | 2,222 | $3.58K | 0.00% | +2,222 | New |